PMID- 31962002
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20210423
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 9
IP  - 5
DP  - 2020 Mar
TI  - Patient-reported symptom burden as a prognostic factor in treatment with 
      first-line cetuximab plus chemotherapy for unresectable metastatic colorectal 
      cancer: Results of Phase II QUACK trial.
PG  - 1779-1789
LID - 10.1002/cam4.2826 [doi]
AB  - BACKGROUND: It remains unclear whether patients' self-perceptions of symptoms at 
      baseline clinically impact the prognostic relevance, treatment efficacy, or 
      toxicity profiles in metastatic colorectal cancer (mCRC) patients treated with 
      the first-line cetuximab and standard chemotherapy. METHODS: The data were 
      collected from a prospective trial that assessed the relationships between 
      quality of life (QOL), treatment efficacy, and adverse events (AEs). RESULTS: The 
      analysis of 137 mCRC patients revealed a significant association between the 
      presence of baseline tumor-related symptoms and a lower overall survival (OS) 
      compared to the absence of symptoms (HR, 2.49; 95% CI, 1.37-4.62; P = .003). The 
      asymptomatic responders had favorable outcomes compared to the symptomatic 
      nonresponders (2-year OS rates: 83.6% and 35.9%, respectively), while the 
      symptomatic responders had similar outcomes to the asymptomatic nonresponders. 
      The median postprogression survival differed significantly: 10.2 months for the 
      symptomatic patients and 15.9 months for the asymptomatic patients (HR, 2.29; 95% 
      CI, 1.25-4.29, P = .008). The objective response rates and patient toxicity 
      profiles were similar irrespective of the severity of baseline symptoms. 
      CONCLUSION: Baseline symptoms were associated with worse OS but not with impaired 
      treatment efficacy or more frequent AEs in mCRC patients treated with cetuximab 
      in addition to chemotherapy.
CI  - (c) 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Ooki, Akira
AU  - Ooki A
AUID- ORCID: 0000-0001-7618-5775
AD  - Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of 
      Japanese Foundation for Cancer Research, Tokyo, Japan.
FAU - Morita, Satoshi
AU  - Morita S
AD  - Department of Biomedical Statistics and Bioinformatics, Kyoto University, Kyoto, 
      Japan.
FAU - Iwamoto, Shigeyoshi
AU  - Iwamoto S
AD  - Cancer Center, Aichi Medical University, Nagakute, Japan.
FAU - Hara, Hiroki
AU  - Hara H
AD  - Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan.
FAU - Tanioka, Hiroaki
AU  - Tanioka H
AD  - Department of Clinical Oncology, Kawasaki Medical School, Kurashiki, Japan.
FAU - Satake, Hironaga
AU  - Satake H
AD  - Cancer Treatment Center, Kansai Medical University Hospital, Osaka, Japan.
FAU - Kataoka, Masato
AU  - Kataoka M
AD  - Department of Surgery, National Hospital Organization Nagoya Medical Center, 
      Nagoya, Japan.
FAU - Kotaka, Masahito
AU  - Kotaka M
AD  - Gastrointestinal Cancer Center, Sano Hospital, Kobe, Japan.
FAU - Kagawa, Yoshinori
AU  - Kagawa Y
AD  - Department of Surgery, Kansai Rosai Hospital, Amagasaki, Japan.
FAU - Nakamura, Masato
AU  - Nakamura M
AD  - Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Japan.
FAU - Shingai, Tatsushi
AU  - Shingai T
AD  - Department of Surgery, Osaka Saiseikai Senri Hospital, Suita, Japan.
FAU - Ishikawa, Masashi
AU  - Ishikawa M
AD  - Department of Surgery, Shikoku Central Hospital, Shikokuchuo, Japan.
FAU - Miyake, Yasuhiro
AU  - Miyake Y
AD  - Department of Surgery, Osaka Minato Central Hospital, Osaka, Japan.
FAU - Suto, Takeshi
AU  - Suto T
AD  - Department of Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan.
FAU - Hashiguchi, Yojiro
AU  - Hashiguchi Y
AD  - Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan.
FAU - Yabuno, Taichi
AU  - Yabuno T
AD  - Department of Surgery, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
FAU - Sakamoto, Junichi
AU  - Sakamoto J
AD  - Tokai Central Hospital, Kakamigahara, Japan.
FAU - Tsuji, Akihito
AU  - Tsuji A
AD  - Department of Medical Oncology, Kagawa University, Kita, Japan.
FAU - Ando, Masahiko
AU  - Ando M
AD  - Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
FAU - Yamaguchi, Kensei
AU  - Yamaguchi K
AD  - Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of 
      Japanese Foundation for Cancer Research, Tokyo, Japan.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200121
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - PQX0D8J21J (Cetuximab)
SB  - IM
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse 
      effects
MH  - Cetuximab/*administration & dosage/adverse effects
MH  - Colorectal Neoplasms/complications/diagnosis/*drug therapy
MH  - Drug-Related Side Effects and Adverse Reactions/*diagnosis/etiology
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - *Patient Reported Outcome Measures
MH  - Prognosis
MH  - Progression-Free Survival
MH  - Prospective Studies
MH  - *Quality of Life
MH  - Response Evaluation Criteria in Solid Tumors
MH  - Self Report/statistics & numerical data
MH  - Severity of Illness Index
PMC - PMC7050093
OTO - NOTNLM
OT  - cetuximab
OT  - chemotherapy
OT  - colorectal cancer
OT  - quality of life
OT  - symptom
EDAT- 2020/01/22 06:00
MHDA- 2021/04/24 06:00
PMCR- 2020/01/21
CRDT- 2020/01/22 06:00
PHST- 2019/09/20 00:00 [received]
PHST- 2019/12/13 00:00 [revised]
PHST- 2019/12/22 00:00 [accepted]
PHST- 2020/01/22 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
PHST- 2020/01/22 06:00 [entrez]
PHST- 2020/01/21 00:00 [pmc-release]
AID - CAM42826 [pii]
AID - 10.1002/cam4.2826 [doi]
PST - ppublish
SO  - Cancer Med. 2020 Mar;9(5):1779-1789. doi: 10.1002/cam4.2826. Epub 2020 Jan 21.